Drug of Choice Cheatsheet — Hematology (MRCP Part 1)

TL;DR

This drug of choice cheatsheet — hematology focus (MRCP Part 1) provides a high-yield list of first-line treatments for common haematological conditions as tested on MRCP Part 1. It is designed for quick recall under exam conditions and helps you link condition → treatment → rationale quickly. Use it alongside practice questions and timed mocks to boost your confidence.

Why this matters

In the MRCP Part 1 exam, haematology questions frequently include pharmacologic management: “What is the best first-line drug?” Knowing the correct drug quickly enables efficient answering and avoids getting bogged in distractors. A precise cheatsheet supports rapid recall and helps maximise marks under timed conditions. At Crack Medicine, we embed these high-yield therapy links into our resources to help you convert knowledge into exam-ready speed.

Core high-yield drug choices

Here are the 10 most common haematology drug-of-choice points you should attach to memory. Each entry: Condition → Drug of choice → Why it counts for MRCP.

Condition	Drug of Choice	Rationale
Iron deficiency anaemia (without malabsorption)	Oral ferrous sulphate	First-line, cheap and effective; parenteral only if intolerance or absorption problem.
Pernicious anaemia / B12 deficiency	IM hydroxocobalamin	B12 absorption impaired → need parenteral; avoids neurological damage.
Folate deficiency (isolated)	Oral folic acid	Replace folate pool; ensure B12 deficiency is excluded first.
Warm autoimmune haemolytic anaemia (AIHA)	Prednisolone	Steroids remain first-line in warm AIHA. PMC+2NICE+2
Cold agglutinin disease (CAD)	Avoid cold exposure ± Rituximab	Cold-antibody disease: avoid exposure; Rituximab increasingly used. PMC+1
Aplastic anaemia (idiopathic severe)	Antithymocyte globulin + cyclosporine	Immune suppression to allow marrow recovery. NICE
Thrombotic thrombocytopenic purpura (TTP)	Plasma exchange	Removes ADAMTS13 autoantibody; lifesaving. PMC
Haemophilia A	Recombinant factor VIII	Corrects specific factor deficiency – classic therapy.
Von Willebrand disease (type 1)	Desmopressin (DDAVP)	Releases endogenous vWF/factor VIII – first line in mild cases.
Chronic myeloid leukaemia (CML)	Imatinib	Targeted TKI therapy for BCR-ABL positive disease – high exam relevance.

Mnemonic tip: “Iron, B12, Folate, Steroids, **Cold, Agonist, TTP exchange, Haemophilia, VWD, CML” → IBFSAT HVC (just a rough seed).

Practical example / Mini-case

Case: A 34-year-old male presents with fatigue and dark urine after a cold exposure. Investigations show haemoglobin 80 g/L, reticulocytosis, elevated LDH, low haptoglobin, and a positive direct antiglobulin (DAT) test for IgM. Question: What is the drug of choice? Answer: Avoid cold exposure; consider Rituximab in cold-agglutinin disease. Explanation: Cold-antibody AIHA (autoantibodies IgM) is managed initially by avoiding cold triggers; steroid response is poor. Rituximab is increasingly regarded as first-line in CAD. PMC+1

Study-tip checklist

1. Memorise one “best” drug per condition rather than multiple alternatives.

2. Link drug → mechanism → clue in vignette so you identify distractors quickly.

3. Use spaced QBank sessions from Free MRCP MCQs to test recognition.

4. Timed mock practice (via Start a mock test) to build speed and confidence.

5. Review the “why not” alternatives — e.g., why folate alone is wrong if B12 deficiency isn’t excluded, or why steroids don’t reliably work in CAD.

6. Update for UK guidelines – for example, registry evidence for Rituximab in AIHA.

7. Final revision week: memory-dump the table onto a one-page sheet and rehearse it aloud.

Common pitfalls

• Confusing TTP (plasma exchange) with ITP (first-line prednisolone).

• Treating B12 deficiency with folate first — this may mask and worsen neuropathy.

• Presuming iron therapy will work in anaemia of chronic disease when it won’t.

• Forgetting that cold-agglutinin disease management is primarily non-drug (avoid cold) and steroids are less effective.

• Assuming Imatinib is indicated for ALL; it is specific to BCR-ABL positive CML.

• Omitting checklist step of excluding B12 deficiency before treating folate deficiency.

FAQs

Q1: How are “drug of choice” questions phrased in MRCP Part 1?

They typically appear as brief clinical vignettes with a question like: “What is the most appropriate initial treatment?” Recognising the condition quickly leads to the right drug.

Q2: Do I need to memorise doses for MRCP Part 1?

No — the focus is on selecting the correct drug, not specific dosing. Understanding mechanism and indication matters more than exact mg amounts.

Q3: Should I memorise all rare haematology drugs?

Focus on those commonly tested in the core haematology syllabus. Rare therapies may appear but usually after you’ve covered high-yield ones thoroughly.

Q4: How much haematology pharmacology appears in MRCP Part 1?Haematology is one of many subjects (approx. 10% of questions) but therapy-based questions are easily high-yield if you know them. studymrcp.com

Q5: Where does this cheatsheet fit into my overall revision?

Use it as a rapid recall tool in your final phase of revision, after you’ve completed full subject coverage and are reinforcing via question banks and timed mocks.

Ready to start?

Take your revision further with Crack Medicine’s specialist resources: our Free MRCP MCQs with therapy-based questions, and timed mock tests to simulate exam conditions. Combine this cheatsheet with these active tools for optimal preparation.

Sources

• MRCP(UK) official examination information: “Examinations – Part 1” (MRCP UK) thefederation.uk+2thefederation.uk+2

• Treatment of autoimmune haemolytic anaemia: NICE advice – Rituximab NICE+1

• Cold agglutinin disease management: PMC article PMC

• Review: Hemolytic anaemia management including first-line steroids in warm AIHA PMC+1

• MRCP Part 1 subject weightages and format studymrcp.com+1